80% Leverage, 5.5x EBITDA: Is Cresco The High-Risk, High-Reward Play Investors Need?
80% Leverage, 5.5x EBITDA: Is Cresco The High-Risk, High-Reward Play Investors Need?
80% 槓桿率，5.5倍 EBITDA： Cresco 是投資者需要的高風險高回報投資嗎？
Despite flat earnings and challenging market conditions, Cresco Labs Inc. (OTC:CRLBF) remains an "Overweight" stock, according to analysis firm Zuanic & Associates. In his latest report, Zuanic underscores Cresco's strong positioning in emerging adult-use markets such as Pennsylvania and Ohio while identifying valuation advantages that set the company apart.
儘管收益持平且市場環境艱難，Cresco Labs Inc.（場外交易：CRLBF）依然被分析公司Zuanic & Associates評爲"增持"股票。在他最新的報告中，Zuanic強調了Cresco在賓夕法尼亞州和俄亥俄州等新興成人使用市場的強勢定位，同時識別出使公司與衆不同的估值優勢。
Cresco trades at 5.5x forward EBITDA, below Green Thumb Industries Inc. (OTC:GTBIF) at 7x and Curaleaf Holdings Inc. (OTC:CURLF) at 10x.
Cresco的前向EBITDA爲5.5倍，低於Green Thumb Industries Inc.（場外交易：GTBIF）的7倍和curaleaf holdings inc（場外交易：CURLF）的10倍。
"This discount presents an appealing entry point for investors looking beyond short-term volatility," Zuanic writes.
Zuanic寫道："這一折扣爲那些希望超越短期波動的投資者提供了一個吸引人的入場點。"
Get Benzinga's exclusive analysis and the top news about the cannabis...
在Benzinga獲取獨...
登入免費觀看全文
登入/註冊
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間